Mohamed S. IMAM, Wael Z. KHALED, Mohamed E.A. ABDELRAHİM, Ahmed A.H ALİ, Lobna M. E. SHALABY

Is vancomycin monitoring of real value in pediatric cancer patients?

Vancomycin is not nephrotoxic by itself but many patients using it with other nephrotoxic agents show nephrotoxicity to some extent. Whether to monitor or not to monitor vancomycin needs further study. The aim of the present study was to investigate the significance of monitoring vancomycin serum levels in pediatric patients treated from different malignancies. 150 newly diagnosed pediatric patients, with various types of malignancy treated with different nephrotoxic agents including vancomycin, were recruited in the study. All patients had normal renal functions at the start of the study and were divided into three groups; Group I included 50 (21 females) patients received vancomycin without monitoring (VWOM group); Group II included 50 (19 females) patients received vancomycin with monitoring (VWM group); Group III (Control group) included 50 (23 females) patients received vancomycin-free antimicrobial agents (VF group). Vancomycin trough level was determined only for VWM group. The effectiveness of monitoring was estimated by the ability to achieve more rapid response, decrease hospital stay and nephrotoxicity and its effect on total dose of vancomycin. There was a significant decrease in nephrotoxicity in VWM and VF groups, 9 subjects (18%), compared to 15 subjects (30%) in VWOM group (p=0.016). The time needed to show a response achievement was significantly decreased in VWM group compared to VWOM group with mean (SD) of 6.5 (2.5) and 8.7 (3.6) days, respectively (p=0.015). That led to shorter hospital stay in VWM group compared to VWOM group with mean (SD) of 10.1 (3.4) and 12.4 (4.2) days, respectively (p=0.003). Monitoring vancomycin level was important in the examined high risk groups of pediatric cancer patients studied.

PDF

___

Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis. 2004;39(Supplement 1):S25-S31.

Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis. 2004;39(Supplement 1):S7-S10.

Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993;32(2):325-4.

Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25(4):679-87.

Winter ME, Koda-Kimble MA, Young LY. Basic clinical pharmacokinetics. 5th ed: Lippincott Williams, Wilkins Philadelphia; 2009.

Lodise TP, Lomaestro B, Graves J, Drusano G. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330-6.

Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29(6):1107-15.

Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138-44.

Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. AJHP. 2009;66(1):82-98.

Cole TS, Riordan A. Vancomycin dosing in children: what is the question? Arch Dis Child. 2013;98(12):994-7.

Sammons HM, Starkey E. Vancomycin use in neonates and children: evidencebased practice is needed. Arch Dis Child. 2013;98(6):447-8.

Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42(Supplement 1):S5-S12.

Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer J, Crossley K, Riff LJ. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32(6):848-52.

Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH; National Kidney Disease Education Program Laboratory Working Group. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006;52(1):5-18.

McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158(3):422-6.

Lee K, Phelps S. Implementation of vancomycin monitoring criteria in a pediatric hospital. J Pediatr Pharmacol Ther. 2004;9:179-86.

Young TE, Mangum B. Neofax 2008. Physician’s Desk Reference: Thomson Reuters; 2008.

Taketomo CK, Kraus DM, Hodding JH. Pediatric Dosage Handbook: Including Neonatal dosing, drug administration, and extemporaneous preparations. 17th edition ed: Lexi-Comp; 2010.

Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DF. Mississippi Mud No More: Cost-Effectiveness of Pharmacokinetic Dosage Adjustment of Vancomycin to Prevent Nephrotoxicity. Pharmacotherapy 2003;23(5):643-50.

Khotaei GT, Ashtiani MTH. Monitoring of serum vancomycin concentrations in pediatric patients with normal renal function. Acta Med Iranica. 2010;48(2):91-4.

Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull. 2003;26(6):876-9.

Chang D, Liem L, Malogolowkin M. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. Pediatr Infect Dis J. 1994;13(11):969-74.

Mariani-Kurkdjian P, Nebbad H, Aujard Y, Bingen E. Monitoring serum vancomycin concentrations in the treatment of Staphylococcus infections in children. Arch Pediatr. 2008;15(11):1625-9.

del Mar Fernández de Gatta M, Calvo MV, Hernández JM, Caballero D, San Miguel JF, Domínguez-Gil A. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther. 1996;60(3):332-40.

Abdelaziz K, Abdelrahim ME. Identification and categorisation of drugrelated problems on admission to an adult intensive care unit. European J Hospital Pharm. 2015;22(3):138-41.

Kitzis M, Goldstein F. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infec. 2006;12(1):92-5.

Omote S, Yano Y, Hashida T, Masuda S, Yano I, Katsura T, Inui K. A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. Biol Pharm Bull. 2009;32(1):99-104.